RxDoctor Payments Data

Heather Back, DO

Family Medicine · West Des Moines, IANPI 1750545364

Payments from drug & device makers

$618in general payments, 2019–2025

Across 12 payments — averaging $51.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$128
  • Biohaven Pharmaceuticals, Inc.$125
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$111
  • Pfizer$88
  • Johnson & Johnson$80
  • Lilly USA, LLC$31
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$618100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$618 in reported general payments places this provider in the 75th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$90,718
Medicare patients
201
Services billed
1,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$45,590
EliquisApixaban38$40,329
MounjaroTirzepatide13$16,167
XareltoRivaroxaban12$8,722
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,603
Atorvastatin Calcium267$1,979
Levothyroxine Sodium229$1,964
Venlafaxine Hcl ErVenlafaxine Hcl22$1,573
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$924
Albuterol Sulfate HfaAlbuterol Sulfate30$921
Bupropion XlBupropion Hcl42$914
Omeprazole66$899
Duloxetine Hcl38$832
Rosuvastatin Calcium89$790
Nano 2nd Gen Pen NeedlePen Needle, Diabetic16$744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$45,59035 claims
PfizerEliquis$88$40,32938 claims
Lilly USA, LLCMounjaro$31$16,16713 claims
Johnson & JohnsonXarelto$80$8,72212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →